Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg
Glenmark needs to work harder on reducing its debt
Glenmark expects to generate 400 crore free cash flows in FY22, which could help the company pare its debts Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
Earnings Call for Q4FY21 of Glenmark Pharmaceuticals
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript. Glenmark Pharmaceuticals Ltd - 532296 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31st March, 2021
Glenmark Pharma Q4 results: PAT jumps 6% to Rs 234 crore
For the fiscal ended March this year, the company posted a net profit of Rs 970.1 crore as against Rs 776 crore in the previous fiscal Glenmark Pharmaceuticals Ltd - 532296 - Board recommends Dividend
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 28, 2021, inter alia, has recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2020 - 21 subject to the approval of the Shareholders at the ensuing Annual General Meeting. GLENMARK PHARMACEUTICALS LTD. - 532296 - Board recommends Dividend
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 28, 2021, inter alia, has recommended Dividend @ 250% i.e. Rs. 2.50/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2020 - 21 subject to the approval of the Shareholders at the ensuing Annual General Meeting.